HomeCompareBVNKF vs ARCC

BVNKF vs ARCC: Dividend Comparison 2026

BVNKF yields 6.73% · ARCC yields 10.65%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BVNKF wins by $6.7K in total portfolio value· pulled ahead in Year 2
10 years
BVNKF
BVNKF
● Live price
6.73%
Share price
$29.71
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$31.2K
Annual income
$1,032.71
Full BVNKF calculator →
ARCC
Ares Capital Corporation
● Live price
10.65%
Share price
$18.02
Annual div
$1.92
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.5K
Annual income
$1.14
Full ARCC calculator →

Portfolio growth — BVNKF vs ARCC

📍 BVNKF pulled ahead of the other in Year 2

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBVNKFARCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BVNKF + ARCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BVNKF pays
ARCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BVNKF
Annual income on $10K today (after 15% tax)
$572.20/yr
After 10yr DRIP, annual income (after tax)
$877.80/yr
ARCC
Annual income on $10K today (after 15% tax)
$905.66/yr
After 10yr DRIP, annual income (after tax)
$0.97/yr
At 15% tax rate, BVNKF beats the other by $876.83/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BVNKF + ARCC for your $10,000?

BVNKF: 50%ARCC: 50%
100% ARCC50/50100% BVNKF
Portfolio after 10yr
$27.9K
Annual income
$516.93/yr
Blended yield
1.86%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ARCC right now

BVNKF
No analyst data
Altman Z
6.8
Piotroski
8/9
ARCC
Analyst Ratings
24
Buy
7
Hold
Consensus: Buy
Price Target
$21.88
+21.4% upside vs current
Range: $21.00 — $23.00
Altman Z
0.8
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BVNKF buys
0
ARCC buys
0
No recent congressional trades found for BVNKF or ARCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBVNKFARCC
Forward yield6.73%10.65%
Annual dividend / share$2.00$1.92
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-50%
Portfolio after 10y$31.2K$24.5K
Annual income after 10y$1,032.71$1.14
Total dividends collected$8.6K$1.1K
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: BVNKF vs ARCC ($10,000, DRIP)

YearBVNKF PortfolioBVNKF Income/yrARCC PortfolioARCC Income/yrGap
1$11,373$673.17$11,373$532.74$0.00ARCC
2← crossover$12,885$715.53$12,608$279.46+$277.00BVNKF
3$14,544$757.60$13,809$142.90+$735.00BVNKF
4$16,362$799.23$15,042$72.20+$1.3KBVNKF
5$18,347$840.27$16,341$36.27+$2.0KBVNKF
6$20,512$880.60$17,732$18.18+$2.8KBVNKF
7$22,868$920.10$19,231$9.10+$3.6KBVNKF
8$25,428$958.68$20,851$4.55+$4.6KBVNKF
9$28,204$996.24$22,605$2.28+$5.6KBVNKF
10$31,211$1,032.71$24,504$1.14+$6.7KBVNKF

BVNKF vs ARCC: Complete Analysis 2026

BVNKFStock

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN (freeze-dried) that has completed Phase III clinical trials for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase II clinical trial for the treatment of SARS-CoV-2; and TAEK-VAC, which is in Phase I/II clinical trial for treatment of advanced HER2 and brachyury-expressing cancers. It has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. The company operates in the United States, Belgium, Germany, the Netherlands, Sweden, Switzerland, Austria, the United Kingdom, Japan, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.

Full BVNKF Calculator →

ARCCBDC

Ares Capital Corporation is a business development company specializing in acquisition, recapitalization, mezzanine debt, restructurings, rescue financing, and leveraged buyout transactions of middle market companies. It also makes growth capital and general refinancing. It prefers to make investments in companies engaged in the basic and growth manufacturing, business services, consumer products, health care products and services, and information technology service sectors. The fund will also consider investments in industries such as restaurants, retail, oil and gas, and technology sectors. It focuses on investments in Northeast, Mid-Atlantic, Southeast and Southwest regions from its New York office, the Midwest region, from the Chicago office, and the Western region from the Los Angeles office. The fund typically invests between $20 million and $200 million and a maximum of $400 million in companies with an EBITDA between $10 million and $250 million. It makes debt investments between $10 million and $100 million The fund invests through revolvers, first lien loans, warrants, unitranche structures, second lien loans, mezzanine debt, private high yield, junior capital, subordinated debt, and non-control preferred and common equity. The fund also selectively considers third-party-led senior and subordinated debt financings and opportunistically considers the purchase of stressed and discounted debt positions. The fund prefers to be an agent and/or lead the transactions in which it invests. The fund also seeks board representation in its portfolio companies.

Full ARCC Calculator →
📬

Get this BVNKF vs ARCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BVNKF vs SCHDBVNKF vs JEPIBVNKF vs OBVNKF vs KOBVNKF vs MAINBVNKF vs HTGCBVNKF vs GBDCBVNKF vs ORCC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.